Clinical Trial Update: A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® [Phase 3]

View source ↗

Summary

A single-arm 48-week safety follow-up study assessing Tobrineb/Actitob/Bramitob against TOBI in cystic fibrosis patients; phase 3 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Actitob (tobramycin inhalation solution)
• Bramitob (tobramycin inhalation solution)
• TOBI (Tobramycin inhalation solution)
• Tobrineb (tobramycin inhalation solution)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED